About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker SNDX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer…
NCT07923071 · Relapsed/Refractory (R/R) Hematologic Malignancies, Acute L…
Revumenib
SNDX
Syndax Pharmaceuticals
Phase 1Not yet recruiting18Jan 2030Registry ↗
Oct 21, 2026Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leuk…
NCT07211958 · Acute Myeloid Leukemias
Revumenib, Placebo
SNDX
Syndax Pharmaceuticals
Phase 3Recruiting468Jun 2029Registry ↗
Oct 9, 2026A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1…
NCT04065399 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
revumenib, cobicistat
SNDX
Syndax Pharmaceuticals
Phase 1/2Recruiting447Dec 15, 2027Registry ↗
Sep 16, 2026A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid…
NCT06226571 · Acute Myeloid Leukemias
Revumenib, Chemotherapy Regimen
SNDX
Syndax Pharmaceuticals
Phase 1Active, not recruiting96Feb 2027Registry ↗
Jul 6, 2026Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05731947 · Colorectal Cancer, Solid Tumors
Revumenib, Chemotherapy
SNDX
Syndax Pharmaceuticals
Phase 1/2Terminated41Jun 30, 2025Registry ↗
Jun 16, 2026A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (…
NCT04710576 · Chronic Graft-versus-host-disease
Axatilimab
SNDX
Syndax Pharmaceuticals
Phase 2Recruiting296Apr 7, 2023Registry ↗
Mar 27, 2026MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256 · Idiopathic Pulmonary Fibrosis
Axatilimab, Placebo
SNDX
Syndax Pharmaceuticals
Phase 2Active, not recruiting145Sep 2026Registry ↗
Sep 15, 2025A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
NCT03604692 · Chronic Graft-versus-host-disease
axatilimab
SNDX
Syndax Pharmaceuticals
Phase 1/2Completed41Aug 12, 2022Registry ↗
Sep 5, 2025Expanded Access Program for Revumenib
NCT05918913 · Relapsed/Refractory Acute Leukemia
Revumenib
SNDX
Syndax Pharmaceuticals
—No longer available——Registry ↗
Mar 20, 2025Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC)…
NCT02437136 · Non-Small Cell Lung Cancer, Melanoma
entinostat, pembrolizumab
SNDX
Syndax Pharmaceuticals
Phase 1/2Completed191Sep 29, 2022Registry ↗
Jan 10, 2025Study of Radiolabeled Revumenib in Adults With Acute Leukemia
NCT05406817 · Acute Leukemia
Revumenib
SNDX
Syndax Pharmaceuticals
Phase 1Completed9Nov 18, 2024Registry ↗
Dec 4, 2024Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Pha…
NCT02708680 · Breast Cancer
Entinostat, Atezolizumab
SNDX
Syndax Pharmaceuticals
Phase 1/2Completed89Mar 31, 2021Registry ↗
Aug 13, 2024A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516 · Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
Revumenib, Chemotherapy Regimen 1
SNDX
Syndax Pharmaceuticals
Phase 1Completed30Jul 29, 2024Registry ↗
May 17, 2024A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With…
NCT03238027 · Solid Tumor, Metastatic Tumor
Axatilimab, Durvalumab
SNDX
Syndax Pharmaceuticals
Phase 1Completed45Nov 20, 2020Registry ↗
Jan 10, 2024Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
NCT02915523 · Epithelial Ovarian Cancer, Peritoneal Cancer
entinostat, avelumab
SNDX
Syndax Pharmaceuticals
Phase 1/2Completed140Feb 21, 2019Registry ↗
Jul 6, 2023A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carc…
NCT00750698 · Non Small Cell Lung Cancer
Entinostat, Erlotinib
SNDX
Syndax Pharmaceuticals
Phase 2Terminated8May 2010Registry ↗
Aug 22, 2022Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With…
NCT00602030 · Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lu…
Entinostat, Placebo
SNDX
Syndax Pharmaceuticals
Phase 1/2Completed141Feb 4, 2010Registry ↗
Jul 22, 2022A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement S…
NCT04415073 · Coronavirus, COVID
SNDX-6352, Placebo
SNDX
Syndax Pharmaceuticals
Phase 2Terminated1Jul 13, 2020Registry ↗
Jun 30, 2022Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI)…
NCT00828854 · ER+ Breast Cancer
Entinostat, Aromatase Inhibitor (AI) Therapy
SNDX
Syndax Pharmaceuticals
Phase 2Completed27Nov 24, 2009Registry ↗
Jun 6, 2022A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in…
NCT00754312 · Breast Cancer
SNDX-275
SNDX
Syndax Pharmaceuticals
Phase 1Terminated1Feb 28, 2009Registry ↗
May 11, 2022Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal…
NCT00676663 · Breast Cancer, Estrogen Receptor-Positive Breast Cancer
entinostat, exemestane
SNDX
Syndax Pharmaceuticals
Phase 2Completed130Jan 29, 2011Registry ↗
Apr 28, 2022Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02897778 · Neoplasms, Neoplasms, Glandular and Epithelial
Entinostat, Placebo
SNDX
Syndax Pharmaceuticals
Phase 1Completed30Mar 13, 2017Registry ↗
Jan 25, 2022Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid…
NCT02909452 · Neoplasms, Neoplasms, Glandular and Epithelial
Entinostat, Pembrolizumab
SNDX
Syndax Pharmaceuticals
Phase 1Completed30Jul 17, 2019Registry ↗
Dec 15, 2021Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Ca…
NCT02820961 · Breast Cancer, Estrogen Receptor Positive Breast Cancer
entinostat, exemestane
SNDX
Syndax Pharmaceuticals
Phase 1Completed61Sep 10, 2018Registry ↗
Nov 19, 2021Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non…
NCT01594398 · Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
entinostat, entinostat
SNDX
Syndax Pharmaceuticals
Phase 1Completed14Apr 2014Registry ↗
Oct 22, 2019A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgki…
NCT00866333 · Hodgkin's Lymphoma
Entinostat
SNDX
Syndax Pharmaceuticals
Phase 2Terminated49Feb 8, 2013Registry ↗
Aug 16, 2018A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
NCT03187015 · Drug Interaction, Healthy Volunteer
Entinostat, Midazolam
SNDX
Syndax Pharmaceuticals
Phase 1Completed26Jun 4, 2017Registry ↗
Aug 16, 2018Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
NCT02922946 · Volunteers, Healthy Volunteers
Entinostat
SNDX
Syndax Pharmaceuticals
Phase 1Completed47May 20, 2017Registry ↗
Aug 16, 2018A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokine…
NCT02922933 · Volunteers, Healthy Volunteers
entinostat, Omeprazole
SNDX
Syndax Pharmaceuticals
Phase 1Completed66Apr 19, 2017Registry ↗
Apr 13, 2018A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired R…
NCT03192111 · Renal Impairment, Healthy Volunteer
Entinostat
SNDX
Syndax Pharmaceuticals
Phase 1Completed40Nov 23, 2017Registry ↗

30 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:41 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances